Pfizer Leaders, Founders, And Executives Team Members
Pfizer, Inc. has established itself as a global pharmaceutical and biotechnology leader. When the COVID-19 pandemic began, Pfizer became one of the most reliable vaccine providers and government contractors. Read here to learn more about the Pfizer leaders, Founders, and executives team members, and the people behind its success.
Who are the Top Executives of Pfizer Inc.
The Executive Leadership Team is Pfizer’s highest decision-making and leadership group, responsible for the company’s financial, strategic, and operational choices.
Dr. Albert Bourla, Chief Executive Officer and Chairman
Albert Bourla is the current Chief Executive Officer and Board of Directors Chairman of Pfizer. He is responsible for fostering the scientific and commercial development essential to improve people’s health.
Bourla has been with Pfizer for over two decades and became CEO in January 2019. Pfizer underwent a significant transformation under his leadership, becoming a more science-driven and innovative business. Under his leadership, Pfizer is set to put more focus on breakthrough science and medicines in cancer and other diseases by acquiring companies and engaging in deals for the next decade.
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President
Sally Susman leads Pfizer as its Executive Vice President and Chief Corporate Affairs Officer. Her roles at Pfizer include vice chair of the Pfizer Foundation and co-head of the Pfizer Political Action Committee (PAC).
Under Susman’s current role, she oversees the external stakeholders’ activities, including communications, government relations, global policy, investor relations, corporate responsibility, and patient advocacy.
Payal Sahni Becher, Chief People Experience Officer, Executive Vice President
Payal Sahni Becher is Pfizer’s Chief People Experience Officer and Executive Vice President. She is in charge of the company’s global talent acquisition, diversity and inclusion, total rewards, and the experience of the company’s employees.
Becher joined the company as Senior Vice President of Human Resources in 1997. Before her current position, she also became the Vice President, Human Resources for Pfizer Biopharmaceuticals Group, where she implemented HR strategies in the company’s business units.
William Pao, M.D., Ph.D., Chief Development Officer, Executive Vice President
Dr. William Pao is Pfizer’s Chief Development Officer and Executive Vice President. He oversees Global Product Development operations, including clinical development and innovation medicines.
Dr. Pao joined Pfizer in 2022 as the Head of Roche Pharma Research & Early Development. His responsibilities included managing the discovery and early development of a pipeline of novel therapeutic medicines.
William revolutionized cancer genomics, personalized medicine, translational medicine, mechanistic and clinically targeted cancer treatment research, and other medical sectors. His study on lung cancer’s susceptibility and resistance to EGFR tyrosine kinase inhibitors (TKIs) revealed unique molecular pathways, provided essential insights into the molecular basis of lung cancer and other malignancies, and led to the creation of several treatments.
Mike McDermott, Chief Global Supply Officer, Executive Vice President
Mike McDermott oversees all of Pfizer’s production and supply chain operations as Chief Global Supply Officer and Executive Vice President. He and the Pfizer Global Supply (PGS) team ensure the continuous supply of Pfizer’s hundreds of medicines and vaccines. PGS has 30,000 employees and contractors and 39 Pfizer global manufacturing facilities.
During the COVID-19 pandemic, Pfizer has accomplished manufacturing and global distribution of the Pfizer-BioNTech COVID-19 vaccine with the help of McDermott’s leadership.
Aamir Malik, Chief Business Innovation Officer, Executive Vice President
Aamir Malik is the current Executive Vice President and Pfizer’s Chief Business Innovation Officer. He oversees strategy, business development, portfolio, new commercial initiatives, and innovative access relationships with payers and governments worldwide.
Before joining Pfizer, Malik spent 25 years at McKinsey and soon led the company’s Global Pharmaceutical and Medical Products Practice.
Doug Lankler, General Counsel, Executive Vice President
Doug Lankler is currently Pfizer’s General Counsel and Executive Vice President. Lankler joined in 1999 and became the chief compliance and risk officer.
Doug was an Assistant U.S. Attorney for the Southern District of New York at the Department of Justice before he joined the company. Doug was honored with the Distinguished Service Award from the United States Department of Justice. This award honors state, local, and tribal rank-and-file police officers, deputies, and troopers for outstanding policing.
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President
Rady Johnson serves as Pfizer’s Executive Vice President and Chief Compliance, Quality, and Risk Officer. He oversees the company’s worldwide efforts in compliance, quality assurance, security, and the Office of the Ombuds.
Johnson joined Pfizer in 1994 and led the company’s Regulatory Law, Corporate Regulatory, Healthcare Law Audit functions, and Legal Division’s Global Products Counsel. He also became Vice President and Associate General Counsel for the company’s Worldwide Biopharmaceuticals Business. Johnson was also an Ethisphere Institute awardee in 2015.
Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business
Angela Hwang currently serves as Chief Commercial Officer and President of Pfizer’s commercial organization, Global Biopharmaceuticals Business. She is also in charge of fostering new relationships with international payers and governments to expand Pfizer’s reach.
Hwang has been a part of Pfizer for over two decades and has experience in every region and therapeutic area. She leads a team of 26,000 employees in 125 countries that have brought over 600 new medications and goods to people in need of healthcare.
Lidia Fonseca, Chief Digital and Technology Officer, Executive Vice President
Lidia Fonseca serves as Pfizer’s Chief Digital and Technology Officer and Executive Vice President. She is in charge of the digital strategy for the whole company, which includes all digital, data, and technology services and products.
Her team drives innovation in the operational processes at Pfizer through automation and robotics, as well as providing valuable insights with data, sophisticated analytics, and AI for better and more efficient decision-making.
Mikael Dolsten, M.D., Ph.D., Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer Inc.
Dr. Mikael Dolsten currently serves as Pfizer’s Chief Scientific Officer and President of Worldwide Research, Development, and Medical. His primary responsibility is to improve Pfizer’s position as the industry leader in developing small-molecule medicines, gene therapies, biotherapeutics, and vaccines. He is also a member of the Portfolio Strategy and Investment Committee.
Dolsten contributes to molecular cell biology, immunology, and oncology research by inventing patents and publishing his works in international journals.
Dave Denton, Chief Financial Officer and Executive Vice President
Dave M. Denton is Pfizer’s Chief Financial Officer and Executive Vice President. Denton is a core member of Pfizer’s Executive Leadership Team (ELT) and contributes to the company’s worldwide financial strategy. He oversees the company’s financial operations, including auditing, treasury, tax, insurance, OP&A, and business finance and analytics.
Denton has over two decades of financial expertise, particularly in the healthcare industry. He leverages his unique understanding of the healthcare industry, payer dynamics, and patient priorities in helping Pfizer achieve its objectives.
Bill Carapezzi, Executive Vice President, Global Business Services and Transformation
Bill Carapezzi currently serves as Pfizer’s Executive Vice President, Global Business Services and Transformation. He oversees operations for global procurement, global financial shared services, real estate, HR operations, and the economic project management office.
Carapezzi joined Pfizer in 2008, where he was the Vice President of Global Tax. He soon became the company’s Senior Vice President of Global Business Operations.
(Above Images from the Official Pfizer Inc. Website)
Pfizer Inc Board of Directors
Get to know the dynamic board members guiding Pfizer into the future.
- Dr. Albert Bourla, Chief Executive Officer and Chairman
- Shantanu Narayen, Lead Independent Director
- Ronald E. Blaylock
- Joseph J. Echevarria
- Susan Hockfield, Ph.D.
- Suzanne Nora Johnson
- Scott Gottlieb, M.D.
- Dan R. Littman, M.D., Ph.D.
- James Quincey
- Helen H. Hobbs, M.D.
- James C. Smith
- Susan Desmond-Hellmann, M.D., M.P.H
About Pfizer Inc.
Image by Joeahead from Shutterstock.com
Pfizer Inc. is an American multinational pharmaceutical company. The company focuses on medical science and ensures that people in communities can access life-saving medications.
Who founded Pfizer Inc.?
Cousins Charles Pfizer and Charles F. Erhart are the founders of Pfizer Inc, who built the company around 1849. The headquarters of Pfizer Inc is in Williamsburg, New York. The youngest son of Charles Pfizer, Emile Pfizer, served as President of the corporation from 1906 to 1941.
Where is Pfizer’s headquarters?
Pfizer Inc. is a biotechnology and pharmaceutical company with its main office in Manhattan, New York City. It has 18 other offices all over the US.
What Industries Does Pfizer Inc. Serve?
Pfizer collaborates with healthcare providers worldwide to provide high-quality pharmaceuticals and vaccines. Pfizer employs a staff of medical experts and researchers dedicated to treating and preventing some of the world’s deadliest diseases in industrialized and developing nations.
Pfizer leaders and executives work in developed and developing markets to improve health, prevention, treatments, and cures for the most devastating disease of our time. Pfizer’s global portfolio includes medicines, vaccines, and some of the most popular consumer healthcare products globally.